HEALTH CARE AND BROADER SOCIETAL COSTS OF ADHD IN CANADA ARE SUBSTANTIALLY HIGHER THAN EXPECTED
Author(s)
Khalid Lakhdari, MBA, MSc1, Cedric Vinetti, MSc Economics2, Ron Goeree, Professor Emeritus, McMaster University3.
1MS. MBA., Otsuka Pharma, Saint-laurent, QC, Canada, 2Otsuka Pharma, Saint-Laurent, QC, Canada, 3Goeree Consulting Limited, Mount Hope, ON, Canada.
1MS. MBA., Otsuka Pharma, Saint-laurent, QC, Canada, 2Otsuka Pharma, Saint-Laurent, QC, Canada, 3Goeree Consulting Limited, Mount Hope, ON, Canada.
OBJECTIVES: Attention-deficit hyperactivity disorder (ADHD) is a common disorder that is associated with broad functional impairment among children, adolescents, and adults (C,Al,A). These impairments result in significant health care system resource use (HCRU) and out-of-pocket (OOP) costs and productivity losses for parents, patients and caregivers. Although it is important to assess the cost-effectiveness of new ADHD treatments, there is limited data on the cost of managing patients with ADHD in Canada. Therefore, the objective is to estimate the cost of managing C,Al,A patients with ADHD in Canada.
METHODS: A survey was conducted of 5 ADHD health care providers from across Canada to evaluate HCRU and OOP costs for C,Al,A patients with ADHD, including: visits, tests & procedures; time off work and OOP costs. Annual HRCU and costs were collected separately for patients with ADHD who were responding or not responding to treatment. Unit costs were obtained from various Canadian sources ($2026).
RESULTS: For responder C,Al,A patients, estimated annual health care costs were $2,359, $2,600, and $4,682, respectively, OOP costs and productivity losses were $27,515, $15,086 and $4,090, respectively, and total annual costs were $29,874, $17,686 and $8,772, respectively. For non-responder C,Al,A patients, annual health care costs were $7,929, $9,470, and $12,036, respectively, OOP costs and productivity losses were $63,597, $28,973, and $14,595, respectively, and total annual costs were $71,526, $38,443 and $26,639, respectively.
CONCLUSIONS: Overall health care costs were lowest in children and highest in adults. However, for OOP costs and productivity losses the opposite was found, and these costs were estimated to be substantial, such that total costs were highest in children, followed by adolescents and then adults. For both health care and OOP costs and productivity losses, costs were estimated to be substantially higher for patients who did not respond to treatment versus those who responded to treatment.
METHODS: A survey was conducted of 5 ADHD health care providers from across Canada to evaluate HCRU and OOP costs for C,Al,A patients with ADHD, including: visits, tests & procedures; time off work and OOP costs. Annual HRCU and costs were collected separately for patients with ADHD who were responding or not responding to treatment. Unit costs were obtained from various Canadian sources ($2026).
RESULTS: For responder C,Al,A patients, estimated annual health care costs were $2,359, $2,600, and $4,682, respectively, OOP costs and productivity losses were $27,515, $15,086 and $4,090, respectively, and total annual costs were $29,874, $17,686 and $8,772, respectively. For non-responder C,Al,A patients, annual health care costs were $7,929, $9,470, and $12,036, respectively, OOP costs and productivity losses were $63,597, $28,973, and $14,595, respectively, and total annual costs were $71,526, $38,443 and $26,639, respectively.
CONCLUSIONS: Overall health care costs were lowest in children and highest in adults. However, for OOP costs and productivity losses the opposite was found, and these costs were estimated to be substantial, such that total costs were highest in children, followed by adolescents and then adults. For both health care and OOP costs and productivity losses, costs were estimated to be substantially higher for patients who did not respond to treatment versus those who responded to treatment.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE191
Topic
Economic Evaluation, Patient-Centered Research, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Mental Health (including addiction), Neurological Disorders